Ampio Pharmaceuticals to present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) and the 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)

0

ENGLEWOOD, Col., July 28, 2021 / PRNewswire / – Pharmaceutical Ampio (NYSE American: AMPE), a biopharmaceutical company focused on advancing immunology-based therapies for prevalent inflammatory conditions, today announced the details of the presentation of the company’s summary, “Significant Inhibition of TLR7 / CXCL10 signaling axis by LMWF5A in monocytic lines; Implications for COVID-19 and Lupus Nephritis ”, given virtually at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) and the 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA) on 6-9 October 2021.

Ampio’s presentation is based on the Company’s analysis that Ampio’s drug candidate, Ampion ™, currently in clinical study for the treatment of osteoarthritis and hyperinflammation seen with severe COVID-19, inhibits the release of pro-inflammatory cytokines, also known as cytokine storms. .

The presentation will summarize the evidence that treatment using Ampion suppresses Toll Like Receptor 7/8 (TLR7 / 8) signaling in monocytic / macrophage lines and suggests a role for Ampion in the treatment of the disruption of these pathways seen in lupus nephritis as well. as in COVID-19. Toll-like receptors are fundamental innate mechanisms for detecting and responding to pathogens (molecular models associated with pathogens, PAMPs, including viruses such as SARS-Cov2) or damaged cells (molecular models associated with damage, DAMP) by activating a pro-inflammatory cascade in the immune system. cells. Such deregulated hyperactivation of these pathways is associated with the cytokine / chemokine storm seen in severe COVID-19 patients.

Ampio recently announced early positive data in its AP-014 Phase I clinical trial, using Ampion in the treatment of respiratory distress in patients following COVID-19. The study showed that inhaled Ampion reduced all-cause mortality in COVID-19 respiratory distress by 78% compared to standard of care (SOC) alone.

For more information on the presentation of the summary or LUPUS 2021 and CORA, visit https://lupus2021.kenes.com/.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on advancing immunology-based therapies to treat common inflammatory conditions for which treatment options are limited. Ampio’s flagship drug, Ampion ™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and will be eligible for FDA market exclusivity for 12 years after approval as as new organic product under the Organic Product Price Competition and Innovation Act (BPCIA).

Forward-looking statements

Statements by Ampio in this press release that are not historical facts, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified using words such as “believe”, “expect”, “plan”, “anticipate” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations regarding Ampion and its classification, as well as those associated with regulatory approvals and other FDA rulings, the Biologic License Application (BLA), Ampio’s ability to enter into agreements partnership, trials and rulings and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion can be used to treat ARDS induced by COVID-19, all of which inherently are subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in documents filed by Ampio with the Securities and Exchange Commission, including, without limitation, in Ampio’s annual report on Form 10-K and d ‘other documents filed with the Securities and Exchange Commission. Ampio assumes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact
Katie kennedy
[email protected]
610-731-1045

SOURCE Ampio Pharmaceuticals, Inc.


Source link

Leave A Reply

Your email address will not be published.